Bristol-Myers Squibb and Exelixis partner on renal cell carcinoma study

Bristol-Myers Squibb has announced a new collaboration with Exelixis to evaluate a potentially promising new therapy for renal cell carcinoma.

The clinical development alliance will evaluate a new combination of Cabometyx, a small molecule inhibitor of receptor tyrosine kinases developed by Exelixis, and Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo, either alone or used in conjunction with Yervoy.

Both companies will fund the new development programme, which is expected to include a phase III pivotal trial in first-line renal cell carcinoma, with additional trials planned in bladder cancer, hepatocellular carcinoma and potentially other tumour types.

Phase I clinical data has shown the potential benefits of using Cabometyx in combination with Opdivo in patients with previously treated genitourinary tumours.

Dr Fouad Namouni, head of development for oncology at Bristol-Myers Squibb, said: "We look forward to working with Exelixis, bringing together our knowledge and experience in oncology, to evaluate the potential clinical value of combining these therapies to treat multiple tumours."

Both Cabometyx and Opdivo have been approved in Europe for the treatment of certain forms of renal cell carcinoma, and are the subject of ongoing global phase III pivotal trials in hepatocellular carcinoma.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.